GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $6.55.

A number of research firms recently weighed in on GDRX. UBS Group dropped their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Wells Fargo & Company reduced their target price on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Truist Financial decreased their price target on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th. Finally, The Goldman Sachs Group cut their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $4.09, for a total transaction of $43,668.93. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.53% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On GoodRx

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of GoodRx by 3.0% during the first quarter. Vanguard Group Inc. now owns 8,624,872 shares of the company's stock valued at $38,036,000 after purchasing an additional 251,833 shares in the last quarter. Petrus Trust Company LTA raised its holdings in shares of GoodRx by 7.4% during the first quarter. Petrus Trust Company LTA now owns 3,167,015 shares of the company's stock valued at $13,967,000 after purchasing an additional 216,926 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of GoodRx by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock valued at $9,264,000 after buying an additional 369,553 shares during the period. 8 Knots Management LLC purchased a new position in GoodRx in the first quarter worth about $8,106,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of GoodRx by 16.7% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,434,625 shares of the company's stock worth $6,327,000 after acquiring an additional 205,789 shares during the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Stock Down 2.5%

GoodRx stock opened at $4.37 on Friday. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -145.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.16. The firm's fifty day moving average price is $4.27 and its two-hundred day moving average price is $4.53. GoodRx has a 1-year low of $3.68 and a 1-year high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. The business had revenue of $202.97 million during the quarter, compared to the consensus estimate of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The company's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.08 EPS. On average, equities research analysts predict that GoodRx will post 0.13 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.